Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1987-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.31.4.594PMID 3606063PMCID PMC174783
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Acute interstitial nephritis due to drugs].

  1988cited by this paper
• Drug-induced ototoxicity.

  1988cited by this paper
• An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

  1986cited by this paper
• Attenuation of experimental tobramycin nephrotoxicity by ticarcillin

  1985cited by this paper
• Intensive Treatment of Pseudomonas Chest Infection in Cystic Fibrosis: a Comparison of Tobramycin and Ticarcillin, and Netilmicin and Ticarcillin

  1985cited by this paper
• Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.

  1985cited by this paper
• Antibiotic dosage in cystic fibrosis.

  1985cited by this paper
• Recent otological evaluation of aminoglycoside antibiotics.

  1984cited by this paper
• Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin

  1984cited by this paper
• High Frequency Audiometry

  1984cited by this paper
• Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.

  1984cited by this paper
• Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

  1984cited by this paper
• Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.

  1984cited by this paper
• Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.

  1983cited by this paper
• The nephropathy of cystic fibrosis: a human model of chronic nephrotoxicity.

  1982cited by this paper
• Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients

  1982cited by this paper
• Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease

  1982cited by this paper
• A Comparison between Caloric Test A.M. Hallpike-Fitzgerald and Computer Analysis of Electronystagmographic Data

  1982cited by this paper
• ANTIMICROBIAL CHEMOTHERAPY IN CYSTIC FIBROSIS PATIENTS

  1982cited by this paper
• Pharmacokinetics of tobramycin in cystic fibrosis.

  1982cited by this paper
• Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.

  1982cited by this paper
• Good antimicrobial prescribing. Aminoglycosides.

  1982cited by this paper
• Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer.

  1981cited by this paper
• Are Measurements of Urine Enzymes Useful during Aminoglycoside Therapy?

  1981cited by this paper
• Acute interstitial nephritis due to drugs: Review of the literature with a report of nine cases.

  1980cited by this paper
• Drug-induced Ototoxicity

  1980cited by this paper
• Acute Pulmonary Exacerbations in Cystic Fibrosis A Double-blind Trial of Tobramycin and Placebo Therapy

  1980cited by this paper
• Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

  1980cited by this paper
• Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy.

  1980cited by this paper
• Protection from Gentamicin Nephrotoxicity by Cephalothin and Carbenicillin

  1979cited by this paper
• High-Frequency Audiometry: Age and sex variations

  1979cited by this paper
• Aminoglycoside clearance in patients with cystic fibrosis.

  1979cited by this paper
• Pseudomonas aeruginosa : clinical manifestations of infection and current therapy

  1979cited by this paper
• Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.

  1979cited by this paper
• A quasi-free-field transducer system for high-frequency audiometry.

  1977cited by this paper
• Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.

  1976cited by this paper
• Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.

  1976cited by this paper
• Ototoxicity of tobramycin: a clinical overview.

  1976cited by this paper
• Pseudomonas aeruginosa Infections: Persisting Problems and Current Research to Find New Therapies

  1975cited by this paper
• Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.

  1975cited by this paper
• Tables of Critical Values for the Pratt Matched Pair Signed Rank Statistic

  1974cited by this paper
• Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.

  1974cited by this paper
• Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.

  1974cited by this paper
• Aerosol therapy in cystic fibrosis.

  1970cited by this paper

• Hyperfiltration and Elevated Fractional Excretion of Magnesium in Children with Cystic Fibrosis.

  2025cites this paper
• Central auditory system assessment in children and adolescents with cystic fibrosis: electrophysiology and central auditory processing

  2024cites this paper
• [Assessment of the risk of hearing loss in children with cystic fibrosis].

  2024cites this paper
• Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in Patients with Cystic Fibrosis

  2024cites this paper
• A novel label-free colorimetric polyA aptasensing approach based on cationic polymer and silver nanoparticles for detection of tobramycin in milk.

  2022cites this paper
• Advancements in antimicrobial nanoscale materials and self-assembling systems

  2022cites this paper
• Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

  2021cites this paper
• A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis

  2020cites this paper
• Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.

  2020cites this paper
• Incidence of nephrotoxicity with prolonged aminoglycoside exposure in patients with cystic fibrosis

  2020cites this paper
• Impact of CF on the Kidneys

  2020cites this paper
• Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in Cystic Fibrosis

  2020cites this paper
• Vestibulotoxicity in a patient without renal failure after inhaled tobramycin.

  2019cites this paper
• Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.

  2019cites this paper
• Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment

  2018cites this paper
• Triclosan Is an Aminoglycoside Adjuvant for Eradication of Pseudomonas aeruginosa Biofilms

  2018cites this paper
• Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients

  2018cites this paper
• Changes in the inner ear structures in cystic fibrosis patients.

  2017cites this paper
• Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients

  2017cites this paper
• Healthy Mean Volunteers (SD)

  2017cites this paper
• Systemic Aminoglycosides-Induced Vestibulotoxicity in Humans

  2017cites this paper
• Editorial – Journal of Cystic Fibrosis

  2016cites this paper
• Aminoglycosides: old friend…new foe?

  2016cites this paper
• Hearing loss perception in adults with cystic fibrosis

  2016cites this paper
• Aminoglycoside-induced nephrotoxicity in children

  2016cites this paper
• Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review

  2016cites this paper
• High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients

  2015cites this paper
• High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.

  2015cites this paper
• Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.

  2015cites this paper
• Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.

  2014cites this paper
• Nebulized Tobramycin in the Treatment of Adult CF Pulmonary Exacerbations

  2014cites this paper
• An analysis of ototoxicity in children: Audiological detection, clinical practice and genetic susceptibility

  2014cites this paper
• Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary

  2013cites this paper
• Pharmacokinetics and Pharmacodynamics of Once-Daily Administration of Intravenous Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary Exacerbation

  2013cites this paper
• Risk factors for chronic kidney disease in adults with cystic fibrosis.

  2011cites this paper
• Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem on Mucoid and Nonmucoid Pseudomonas aeruginosa Biofilms

  2011cites this paper
• Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions

  2011influential citation
• Side effects of aminoglycosides on the kidney , ear and balance in cystic fibrosis

  2010cites this paper
• No hearing loss after repeated courses of tobramycin in cystic fibrosis patients

  2010cites this paper
• Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis

  2010cites this paper
• Minimizing the toxicity of aminoglycosides in cystic fibrosis

  2010cites this paper
• Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients

  2009cites this paper
• Renal dysfunction in cystic fibrosis: Is there cause for concern?

  2009cites this paper
• Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

  2009cites this paper
• Prevention of chronic Pseudomonas aeruginosa infection in people with cystic fibrosis

  2009cites this paper
• Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa.

  2009cites this paper
• [Anti Pseudomonas aeruginosa antibiotic therapy in cystic fibrosis (exclusion of macrolides)].

  2006cites this paper
• Mucoviscidose : physiopathologie, génétique, aspects cliniques et thérapeutiques

  2006cites this paper
• Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients

  2006cites this paper
• Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use

  2005cites this paper
• Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES).

  2005cites this paper
• Comment traiter l'infection bronchique chronique à Pseudomonas aeruginosa au cours de la mucoviscidose ?

  2003cites this paper
• [How should chronic Pseudomonas aeruginosa bronchial infection be treated in the course of cystic fibrosis?].

  2003cites this paper
• Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.

  2002cites this paper
• Fibrosis quística. Fisiopatología, genética, aspectos clínicos y terapéuticos

  2002cites this paper
• Mucoviscidose: physiopathologie, génétique, aspects cliniques et thérapeutiques

  2002cites this paper
• Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy

  2001cites this paper
• L'antibiothérapie dans la mucoviscidose: II. Stratégie antibiotique

  2000cites this paper
• Prospects for the Prevention and Control of Pseudomonal Infection in Children with Cystic Fibrosis

  2000cites this paper
• [Antibiotic therapy in cystic fibrosis. II Antibiotic strategy].

  2000cites this paper
• Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin

  2000cites this paper
• Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

  2000cites this paper
• Changing Epidemiology of Pseudomonas aeruginosa Infection in Danish Cystic Fibrosis Patients (1974–1995)

  1999cites this paper
• Empirical antimicrobial therapy of mechanically ventilated patients with nosocomial pneumonia.

  1997cites this paper
• Antimicrobial treatment of pulmonary colonization and infection by pseudomonas aeruginosa in cystic fibrosis patients.

  1997cites this paper
• Pharmacokinetics of vancomycin in adult cystic fibrosis patients

  1996cites this paper
• Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis.

  1996cites this paper
• The General Approach to Cystic Fibrosis Pulmonary Infection in Denmark

  1996cites this paper
• Minimisation of aminoglycoside toxicity in patients with cystic fibrosis.

  1996cites this paper
• Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

  1995cites this paper
• Mechanism of action of antibiotics in chronic pulmonary pseudomonas infection.

  1994cites this paper
• Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis.

  1993cites this paper
• [Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration].

  1993cites this paper
• Antibiotic therapy for chronic infection of pseudomonas in the lung.

  1993cites this paper
• Prevention and treatment of infections in cystic fibrosis.

  1992cites this paper
• Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.

  1991cites this paper
• Cystic fibrosis. 7. Management of cystic fibrosis in different countries. Cystic fibrosis in Copenhagen.

  1991cites this paper
• Cystic fibrosis, pathophysiological and clinical aspects

  1990cites this paper
• Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.

  1989cites this paper
• Once-daily aminoglycoside administration: New strategies for an old drug

  1989cites this paper
• Aminoglycoside-induced hearing loss in humans

  1989cites this paper
• The Pseudomonas flora and tobramycin pharmacokinetics in patients with cystic fibrosis

  1989cites this paper
• Potential toxicity of tobramycin given daily in a single large dose.

  1989cites this paper
• Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

  1989cites this paper
• Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.

  1988cites this paper
• Early Events of Lethal Action by Tobramycin in Pseudomonas aeruginosa

  1988cites this paper